Physician profile
Terry Null
NPI 1114025665
$4,675.33
in general payments reported to CMS, 2019-2025
21 companies · $587 in 2025
The $587 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $900 · 2021: $279 · 2022: $192 · 2023: $670 · 2024: $1,052 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $400 · Entertainment: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $400.00 |
| Entertainment | $128.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,094.76 | 2023-2025 | Miebo, Xiidra, Infuse |
| Coopervision INC. | $889.67 | 2020-2022 | |
| Alcon Vision LLC | $804.26 | 2019-2025 | Dailies Total1, Tryptyr, Wavelight Refractive Suite |
| Optos, INC. | $369.55 | 2019-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $244.01 | 2019 | |
| Sun Pharmaceutical Industries INC. | $216.50 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $198.41 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $173.37 | 2019 | |
| Oyster Point Pharma, INC. | $123.65 | 2023 | Tyrvaya |
| Lombart Brothers, INC. | $111.78 | 2019-2024 | Opd-III |
| Notal Vision, INC. | $87.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $71.13 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $70.05 | 2019-2021 | |
| Allergan, INC. | $46.38 | 2021-2022 | |
| Harrow Eye, LLC | $32.09 | 2025 | Vevye |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31.73 | 2022-2024 | |
| Glaukos Corporation | $30.30 | 2022 | |
| Astellas Pharma US INC | $24.99 | 2023 | Izervay |
| Quidel Corporation | $21.28 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Maculogix, INC. | $14.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Null listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.